Reports Q1 revenue $598.121M, consensus $625.9M. “Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine business,” commented Dan Scavilla, President and Chief Executive Officer. “We are encouraged by the continued strong performance in April across these businesses and remain confident in our ability to drive above-market revenue growth as we move forward. We will continue to invest and provide innovative and clinically advanced products and solutions that help our surgeons improve patient care. We remain steadfast in our vision for the future.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- GMED Earnings this Week: How Will it Perform?
- Globus Medical’s Strategic Acquisition of Nevro Corp: A Catalyst for Growth and Market Expansion
- Globus Medical: Strong Market Positioning and Growth Potential Justify Buy Rating
- Globus Medical price target lowered to $88 from $94 at BTIG
- Globus Medical price target lowered to $80 from $82 at Truist
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue